UPDATE: Ladenburg Thalmann Lowers PT on United Therapeutics

Ladenburg Thalmann has published a research report on United Therapeutics UTHR lowering the price target. In the report, Ladenburg Thalmann wrote, "FREEDOM-C2 fails to achieve statistical significance. The primary endpoint was the median hange in 6MWD at week 16 from baseline which showed a 10 meter placebo-corrected increase (p=0.089). Of note, patients at 16 weeks achieved a mean dose of 3.0±1.9mg whereas patients in FREEDOM-M (M) ended 12 weeks at a mean dose of 3.3±1.8mg and from weeks 8-12, the mean dose achieved by patients in FREEDOM-C2 (C2) were lower than in M." Landenburg Thalmann rated United Therapeutics a BUY with a price target lowered from $85.00 to $61.00. United Therapeutics closed Wednesday at $39.91.